Trials / Recruiting
RecruitingNCT06772935
Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- Sponsor
- Affiliated Hospital of Qinghai University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Electroacupuncture treatment of peripheral neuropathy after taxane chemotherapy for breast cancer
Detailed description
Chemotherapy induced peripheral neuropathy has a significant impact on the integrity of chemotherapy cycle and quality of life of breast cancer patients. The latest research reports indicate that electroacupuncture has a certain therapeutic effect on peripheral neuropathy. In addition, existing studies have confirmed that the peripheral neuropathy of breast cancer induced by taxane is related to genetic factors. This study is based on electroacupuncture treatment of peripheral neuropathy induced by paclitaxel drugs, while screening SNPs related to peripheral neuropathy induced by taxane drugs, and establishing a prognostic model. Eligible patients diagnosed as stage I, II or IIIA breast cancer with peripheral neuropathy for at least 2 weeks were assessed by functional cancer treatment assessment/gynecological oncology group neurotoxicity scale (FACT/GOG-NTX) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire CIPN Twenty Item Scale (EORTC QLQ-CIPN20). All items in the above two scales are scored using Likert's 5 and 4 levels. The researchers will temporarily divide the study into two groups, and if necessary, the researchers will add this group. Laboratory personnel are unaware of all clinical and outcome data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Electro-acupuncture | A method of acupuncture that combines acupuncture with a certain frequency of electrical stimulation. Electrical stimulation is a mild level of stimulation intensity that is acceptable to the human body. |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2027-07-01
- Completion
- 2027-12-31
- First posted
- 2025-01-14
- Last updated
- 2025-01-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06772935. Inclusion in this directory is not an endorsement.